Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.

Remicade (infliximab) - J&J

Humira (adalimumab) - AbbVie

tofacitinib - Generic mfg.

Stelara (ustekinumab) - J&J

Rinvoq (upadacitinib) - AbbVie

Entyvio (vedolizumab) - Takeda

http://www.ncbi.nlm.nih.gov/pubmed/42810421

Anna Silverman; Ashwin N Ananthakrishnan; Dhruv Ahuja; Kuan-Hung Yeh; Marianne Hupé; Ola Olén; Ronghui Xu; Sagar B Patel; Shane W Goodwin; Siddharth Singh; Sudheer Kumar Vuyyuru; Vipul Jairath

Sep 30, 2026